Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves GSK’s Boostrix
Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed, or Tdap) is indicated to be given as a single dose to individuals aged ten to 18
Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed, or Tdap) is indicated to be given as a single dose to individuals aged ten to 18
Data presented at the Association of Research in Vision and Ophthalmology (ARVO) show that Xalacom (latanoprost-timolol maleate ophthalmic solution) demonstrated similar reduction of intraocular pressure (IOP) in patients
Primary immunodeficiency is a group of genetic disorders in which the immune system fails to produce adequate amounts of antibodies, thereby predisposing individuals to increased risk of infection.
Under the agreements, Kos has acquired the anti-hypertensive products Teveten (eprosartan mesylate) and Teveten HCT (eprosartan mesylate/hydrochlorothiazide) from Biovail and has obtained exclusive sales and marketing rights to
Trelstar (triptorelin pamoate for injectable suspension) 3.75mg, one-month slow release, is an injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer and
The Pirkka yogurts are the first in a series of scheduled product launches planned for later this year incorporating Forbes’ cholesterol-lowering ingredient into a variety of foods. “Kesko
Under the one-year extension, Metabolex will receive research funding and screening and development milestones from Astellas Pharma (formerly Yamanouchi Pharmaceutical). The two companies initiated their research collaboration, focused
The new dosing regimen for Kaletra (lopinavir/ritonavir) is available in both liquid and soft gel capsule formulations and offers physicians and patients increased flexibility in managing their HIV
Tarceva is the first drug to significantly improve survival in a phase III trial when added to gemcitabine (Eli Lilly’s Gemzar) chemotherapy in first-line pancreatic cancer compared to
Patients with mild Alzheimer’s disease who were given the 800mg twice-daily dose of Flurizan demonstrated a 44% slowing of decline in their performance of activities of daily living,